Evidence & regulatory context
- Mechanism
- Tubulin inhibitor (INHIBITOR; binds to beta tubulin; direct interaction; disease efficacy)
- Target
- CHEMBL2095182 (Tubulin)
- Injury models
- Spinal cord injury · Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- 1992
- Development stage
- Not recorded
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Paclitaxel; Taxol; Abraxane; ABI-007; NSC-125973; Genexol-PM; Apealea; Pazenir; Onxol
- Note
- Not recorded
Clinical trials 12
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Phase III Trial of Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced NSCLC (includes nab-paclitaxel)
Locally Advanced Lung Non-Small Cell Carcinoma
Enrolment: 474 · Results not recorded
A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer
Breast Neoplasms · Metastases, Neoplasm
Enrolment: 100 · Results not recorded
Adjuvant Therapy for High-Risk Localized Breast Cancer Followed by Weekly Abraxane (paclitaxel albumin-stabilized nanoparticle) With Concurrent Herceptin
HER2-positive Breast Cancer · Stage II Breast Cancer · Stage IV Breast Cancer
Enrolment: 60 · Results not recorded
Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in First Line Advanced Pancreatic Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma · Stage IV Pancreatic Cancer
Enrolment: 43 · Results not recorded
Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics
Breast Cancer
Enrolment: 40 · Results not recorded
Paclitaxel-Carboplatin +/- Necitumumab First-Line in Stage IV Squamous NSCLC
Squamous Non Small Cell Lung Cancer
Enrolment: 167 · Results not recorded
Trimodality Protocol (incl. Paclitaxel) for Locally Advanced NSCLC
Lung Cancer
Enrolment: 19 · Results not recorded
Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells With Low Dose IL-2 and GM-CSF (includes nab-paclitaxel)
Metastatic Pancreatic Adenocarcinoma
Enrolment: 2 · Results not recorded
Ramucirumab + Trastuzumab + Weekly Paclitaxel in HER2+ Gastric Cancer
Recurrent/Metastatic Gastric Cancer
Enrolment: 50 · Results not recorded
A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation (includes nab-paclitaxel)
Solid Tumor
Enrolment: 681 · Results not recorded
A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement in Patients With Unresectable Pancreatic Cancer
Pancreatic Adenocarcinoma · Unresectable Pancreatic Carcinoma
Enrolment: 21 · Results not recorded
Phase I Study to Investigate Safety and Determine MTD and RP2D of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in Patients With Advanced Solid Tumor
Advanced Solid Tumor
Enrolment: 19 · Results not recorded
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
RatSpinal cord injuryContusionSprague Dawleyfemalen = n=8 rats in the spinal cord injury control group; four grou…Intrathecal injection approximately 1 mm rostral and caudal to the lesion epicentre; Taxol delivered by implanted Alzet miniosmotic pumpAbout 15 microgram paclitaxel as PTX@Ac-DEX diluted in 10 m…Within 5 minutes after trauma for nanoparticle and vehicle groups
Model: T10 laminectomy followed by weight drop contusion using a 10 g rod (2.5 mm diameter) dropped from 12.5 mm
Both PTX@Ac-DEX and Taxol improved BBB locomotor scores from the first week after surgery to sacrifice at week 4 relative to injury and empty nanoparticle controls, reduced loss of NF200 staining and reduced CS56 (CSPG) deposition at the lesion. GFAP intensity did not differ between groups. A singl…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
MouseIschaemia-reperfusionRenalC57BL/6Malen = A minimum of six mice per experimental groupIntraperitonealPaclitaxel 0.3 mg/kg body weight; colchicine 0.1 mg/kg body…Started on day 1 after ischaemia induction, during the recovery phase after the…
Model: Bilateral renal ischaemia/reperfusion, renal pedicles clamped for 30 min followed by reperfusion
Ischaemia/reperfusion caused alpha-tubulin deacetylation with loss of alpha-TAT1. Paclitaxel given during the recovery phase increased tubulin acetylation, raised p21 and p-chk2, reduced BrdU-positive tubule cells while increasing BrdU-positive interstitial cells, delayed BUN and body weight recove…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
